MarketWatch
These 8 drugs could help fight dementia — and they’re already on the market
📊
AI Sentiment
Positive
6/10
- Home
- NVS
NVS
Novartis AG
as of 03-09-2026 3:52pm EST
$162.92
+$2.90
+1.81%
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | 75267 | City: | N/A |
| Market Cap: | 310.4B | IPO Year: | N/A |
| Target Price: | $118.00 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $97.72 - $170.46 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 2.56% | Revenue Growth (next year): | 4.91% |
| P/E Ratio: | 23.13 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | +8.26% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
Simply Wall St.
Novartis Advances Immunology And Oncology Plans As Valuation Gap Persists
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Novartis Shareholders Approve Dividend Raise, Share Capital Reduction
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
📈
AI Sentiment
Highly Positive
10/10
MT Newswires
Berenberg Raises Price Target on Novartis to $141 From $116, Keeps Hold Rating
âž–
AI Sentiment
Neutral
5/10
Manufacturing Dive
Novartis, Nucor partner US Forged Rings and others expand domestic investments
📈
AI Sentiment
Highly Positive
9/10
Compare NVS vs Leading Stocks
See how NVS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.